在临床实践中，严重的输液相关反应在接受利妥昔单抗治疗的慢性淋巴细胞白血病（CLL）患者中并不常见：一项瑞典全国性观察性研究的结果
Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: results from a Swedish national observational study.
作者信息
Norin Stefan, Björkstrand Bo, Rommel Franz, Timberg Lars, Andersson Per-Ola, Häggström Johan, Aldrin Anders, Hansson Lotta
机构信息
Department of Hematology, Karolinska University Hospital and Karolinska Institutet, SE-17176 Stockholm, Sweden.
Department of Hematology, Karolinska University Hospital and Karolinska Institutet, SE-17176 Stockholm, Sweden.
出版信息
Leuk Res. 2015 Jan;39(1):33-7. doi: 10.1016/j.leukres.2014.09.019. Epub 2014 Nov 13.
There have been concerns about serious infusion-related adverse drug reactions (ADR) with rituximab in chronic lymphocytic leukemia (CLL). We therefore conducted an observational trial in which CLL patients planned for rituximab-containing therapy were eligible. Ninety-six patients from 19 centers were enrolled. The most common regimen was rituximab, fludarabine and cyclophosphamide. Fifty-six patients experienced ADR during rituximab infusion. Reactions ≥ grade 3 occurred in five patients and no cases of tumor lysis syndrome were recorded. Despite a high number of circulating tumor cells few severe ADR were noted. Thus, rituximab-containing regimens can be considered safe for CLL patients in general practice.
慢性淋巴细胞白血病（CLL）患者使用利妥昔单抗时，人们一直担心会出现严重的输液相关药物不良反应（ADR）。因此，我们开展了一项观察性试验，计划接受含利妥昔单抗治疗的CLL患者符合入组条件。来自19个中心的96例患者入组。最常用的方案是利妥昔单抗、氟达拉滨和环磷酰胺。56例患者在利妥昔单抗输注期间出现ADR。5例患者出现≥3级反应，未记录到肿瘤溶解综合征病例。尽管循环肿瘤细胞数量较多，但严重ADR较少。因此，在一般临床实践中，含利妥昔单抗的方案对CLL患者可被认为是安全的。
Zotero 插件